VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it it yet to generate revenues.
More on VKTX's Q2 Earnings
Research and development (R&D) expenses amounted to $60.2 million, compared with $23.8 million incurred in the year-ago period. This significant increase was primarily due to higher costs associated with clinical studies and manufacturing for the company's drug candidates, as well as increased employee-related expenses.
General and administrative expenses amounted to $14.4 million, up 40% year over year, primarily due to higher employee-related expenses.
Shares of VKTX were down 8% in after-market trading yesterday, likely due to a wider-than-expected loss incurred in the quarter on higher operating expenses.
The stock has outperformed the industry so far this year, as seen in the chart below.
Image Source: Zacks Investment Research
As of June 30, 2025, Viking Therapeutics had cash, cash equivalents and short-term investments worth $808 million compared with $852 million as of March 31, 2025.
2025 Guidance
While Viking did not provide hard numbers, it indicated on the conference call that R&D expenses are expected to rise sequentially by approximately 25% to one-third in the third and fourth quarters of 2025 compared with the second quarter.
VKTX's Pipeline Updates
Viking Therapeutics is one of the few biotech stocks that has shown immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and subcutaneous (SC) versions for treating obesity.
Last month, Viking Therapeutics started the phase III VANQUISH program to evaluate VK2735 SC in adult patients with or without type II diabetes (T2D) for 78 weeks. The program consists of two late-stage studies — the VANQUISH-1 study will enroll obese adults with at least one weight-related co-morbid condition, while the VANQUISH-2 study will enroll obese or overweight adults with T2D. VKTX is targeting enrollment of about 4,500 participants for the VANQUISH-1 study and around 1,100 for the VANQUISH-2 study.
Viking is also evaluating the oral formulation of VK2735 in the ongoing phase II VENTURE-Oral Dosing study, which spans over 13 weeks. Data from this study is expected before this year's end.
Additionally, the company reiterated plans to file an investigational new drug application with the FDA in the fourth quarter of 2025 to advance an internally developed amylin agonist program to clinical development for treating obesity.
VKTX's Zacks Rank
Viking currently carries a Zacks Rank #3 (Hold).
Viking Therapeutics, Inc. Price
Viking Therapeutics, Inc. price | Viking Therapeutics, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Akero Therapeutics AKRO, Amarin Corporation AMRN and Agenus AGEN. While AMRN and AKRO sport a Zacks Rank #1 (Strong Buy) each at present, AGEN carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
In the past 90 days, loss per share estimates for Akero's 2025 have improved from $4.08 to $3.93. Loss per share estimates for 2026 have narrowed from $4.30 to $4.27 during the same period. AKRO stock has surged 86% year to date.
Akero's earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 48.90%.
In the past 90 days, loss per share estimates for Amarin's 2025 have improved from $4.60 to $2.30. Loss per share estimates for 2026 have narrowed from $3.87 to $1.50 during the same period. AMRN stock has surged 61% year to date.
Amarin's earnings beat estimates in two of the trailing four quarters, met the mark once and missed the mark on another occasion, delivering an average surprise of 29.11%.
In the past 90 days, Agenus' bottom-line estimates for 2025 have significantly improved from a loss of $3.46 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $3.91 to $1.99. AGEN stock has soared 122% so far this year.
Agenus' earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN) : Free Stock Analysis Report
Amarin Corporation PLC (AMRN) : Free Stock Analysis Report
Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report
Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Are Basic Materials Stocks Lagging Barrick Mining Corporation (B) This Year?
The Basic Materials group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Barrick Mining (B) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Basic Materials sector should help us answer this question. Barrick Mining is a member of the Basic Materials sector. This group includes 238 individual stocks and currently holds a Zacks Sector Rank of #13. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Barrick Mining is currently sporting a Zacks Rank of #1 (Strong Buy). The Zacks Consensus Estimate for B's full-year earnings has moved 18.2% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. Based on the latest available data, B has gained about 36.1% so far this year. In comparison, Basic Materials companies have returned an average of 9.7%. As we can see, Barrick Mining is performing better than its sector in the calendar year. One other Basic Materials stock that has outperformed the sector so far this year is Newmont Corporation (NEM). The stock is up 67.4% year-to-date. Over the past three months, Newmont Corporation's consensus EPS estimate for the current year has increased 31.2%. The stock currently has a Zacks Rank #1 (Strong Buy). Looking more specifically, Barrick Mining belongs to the Mining - Gold industry, which includes 39 individual stocks and currently sits at #43 in the Zacks Industry Rank. Stocks in this group have gained about 53% so far this year, so B is slightly underperforming its industry this group in terms of year-to-date returns. Newmont Corporation is also part of the same industry. Going forward, investors interested in Basic Materials stocks should continue to pay close attention to Barrick Mining and Newmont Corporation as they could maintain their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Barrick Mining Corporation (B) : Free Stock Analysis Report Newmont Corporation (NEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 hours ago
- Yahoo
A Dream Combination: 3 Value Stocks with Growth
(0:30) - Stock Screener: Can You Find Strong Value Stocks With Growth? (6:45) - Tracey's Top Stock Picks (22:25) - Episode Roundup: ADDYY, ARRY, NX Podcast@ Welcome to Episode #413 of the Value Investor Podcast. Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks. Growth stocks continue to rally. This usually depresses value investors who think they can't be in that trade. But what if they could? What if value investors could buy cheap stocks that also have growth? Screening for Value Stocks with Growth There's one key metric value investors can rely on to find value plus growth and that is the PEG ratio. The PEG ratio, first utilized by Warren Buffett's boss and mentor, Benjamin Graham, uses the price-to-earnings (P/E) ratio divided by earnings growth. Investors get the best of both worlds, both value and growth, with one ratio. The PEG must be below 1.0 to get the cheapest stocks. Tracey also added the top Zacks Ranks of #1 (Strong Buy) and #2 (Buy) and screened for stocks over $5 so as to not get any penny stocks. The screen also looks for current average broker recommendations of 2.5 and under. This screen returned 19 matches. 3 Value Stocks with Growth 1. Adidas AG (ADDYY) Adidas, the large cap athletic shoe and apparel company, is expected to see earnings grow 88.3% in 2025 and 47.3% in 2026. Why are Adidas shares down 17.6% over the last 5 sessions? The shoe retailers are facing tariff risks and the possibility of a consumer slowdown. Adidas' price-to-earnings (P/E) ratio isn't as low as others. It's trading at 26x. But with that big growth, the PEG is still low, at 0.5. Is Adidas a deal after this sell-off? 2. Quanex Building Products Corp. (NX) Quanex Building Products is a small cap company with a mark cap of $918 million. It manufactures products for the building industry, both residential and commercial, including doors and windows. Earnings for Quanex are expected to rise 19.6% in 2025 and another 14.1% in 2026. Shares have come down 18.8% year-to-date as building has slowed. With a forward P/E of just 7.4, Quanex has a PEG ratio of 0.5. Quanex also pays a dividend, yielding 1.6%. Should a small cap company like Quanex be on your short list? 3. Array Technologies, Inc. (ARRY) Array Technologies is a small cap company which makes solar tracking technology. The solar industry has been uncertain in 2025 with tariffs and changes to solar incentives. Shares of Array Technologies have fallen 11.7% in the last week. Year-to-date it's up 1%. But earnings are expected to be up 10% in 2025 and 35% in 2026. Array has a low P/E of just 9.9. A P/E ratio under 10 usually indicates a company is dirt cheap. With the expected growth, it has a PEG ratio of 0.46. Should value investors take a chance on Array Technologies? What Else Should You Know About Value Stocks with Growth? Tune into this week's podcast to find out. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Adidas AG (ADDYY) : Free Stock Analysis Report Quanex Building Products Corporation (NX) : Free Stock Analysis Report Array Technologies, Inc. (ARRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
14 hours ago
- Yahoo
Citi Remains Bullish on Sana Biotechnology (SANA)
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best biotech penny stocks to buy right now. Citi analyst Samantha Semenkow maintained a bullish stance on Sana Biotechnology, Inc. (NASDAQ:SANA), giving it a Buy rating on July 2 with a $15 price target. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The analyst based the rating on Sana Biotechnology, Inc.'s (NASDAQ:SANA) potential in addressing notable market opportunities. Semenkow stated that the company's Type 1 Diabetes (T1D) program has exhibited considerable proof-of-concept results, with updated six-month data showing durable c-peptide production and successful graft survival without the need for immunosuppression. According to the analyst, this data consistency bolsters confidence in Sana Biotechnology, Inc.'s (NASDAQ:SANA) approach and paints a positive picture for its T1D asset, SC451, anticipated to make progress towards an IND as early as 2026. The same day, Morgan Stanley analyst Maxwell Skor also assumed coverage of Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and $12 price target. The analyst expects an investigational new drug filing as early as next year for its proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
